These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
367 related items for PubMed ID: 20714932
1. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, Kulozik AE, Mall MA, Hoffmann GF. J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932 [Abstract] [Full Text] [Related]
2. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA. Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230 [Abstract] [Full Text] [Related]
3. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. Krulišová V, Balaščaková M, Skalická V, Piskáčková T, Holubová A, Paděrová J, Křenková P, Dvořáková L, Zemková D, Kračmar P, Chovancová B, Vávrová V, Stambergová A, Votava F, Macek M. Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207 [Abstract] [Full Text] [Related]
8. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP. Teper A, Smithuis F, Rodríguez V, Salvaggio O, Maccallini G, Aranda C, Lubovich S, Zaragoza S, García-Bournissen F. Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477 [Abstract] [Full Text] [Related]
9. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net. Sommerburg O, Stahl M, Hämmerling S, Gramer G, Muckenthaler MU, Okun J, Kohlmüller D, Happich M, Kulozik AE, Mall MA, Hoffmann GF. J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021 [Abstract] [Full Text] [Related]
10. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study. Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge AM, Fournier D, Duplantie J, Giguère Y, Gekas J, Gagné C, Rousseau F, Reinharz D. J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947 [Abstract] [Full Text] [Related]
16. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB. Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476 [Abstract] [Full Text] [Related]